|
1.
|
Giudice LC and Kao LC: Endometriosis.
Lancet. 364:1789–1799. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Farquhar C: Endometriosis. BMJ.
334:249–253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Sampson JA: Ovarian hematomas of
endometrial type (perforating hemorrhagic cysts of the ovary) and
implantation adenomas of endometrial type. Boston Med Surg J.
186:445–456. 1922. View Article : Google Scholar
|
|
4.
|
Dammann R, Yang G and Pfeifer GP:
Hypermethylation of the cpG island of Ras association domain family
1A(RASSF1A), a putative tumor suppressor gene from the 3p21.3
locus, occurs in a large percentage of human breast cancers. Cancer
Res. 61:3105–3109. 2001.PubMed/NCBI
|
|
5.
|
Agathanggelou A, Honorio S, Macartney DP,
et al: Methylation associated inactivation of RASSF1A from region
3p21.3 in lung, breast and ovarian tumours. Oncogene. 20:1509–1518.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Jo H, Kim JW, Kang GH, et al: Association
of promoter hypermethylation of the RASSF1A gene with prognostic
parameters in endometrial cancer. Oncol Res. 16:205–209.
2006.PubMed/NCBI
|
|
7.
|
Kuzmin I, Liu L, Dammann R, et al:
Inactivation of RAS association domain family 1A gene in cervical
carcinomas and the role of human papillomavirus infection. Cancer
Res. 63:1888–1893. 2003.PubMed/NCBI
|
|
8.
|
Burbee DG, Forgacs E, Zöchbauer-Müller S,
et al: Epigenetic inactivation of RASSF1A in lung and breast
cancers and malignant phenotype suppression. J Natl Cancer Inst.
93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Starzinski-Powitz A, Gaetje R, Zeitvogel
A, et al: Tracing cellular and molecular mechanisms involved in
endometriosis. Hum Reprod Update. 4:724–729. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wu Y, Strawn E, Basir Z, Halverson G and
Guo SW: Promoter hypermethylation of progesterone receptor isoform
B (PR-B) in endometriosis. Epigenetics. 1:106–111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Wu Y, Strawn E, Basir Z, Halverson G and
Guo SW: Aberrant expression of deoxyribonucleic acid
methyltransferases DNMT1, DNMT3A, and DNMT3B in women with
endometriosis. Fertil Steril. 87:24–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Canis M, Donnez JG, Guzick DS, et al:
Revised American Society for Reproductive Medicine classification
of endometriosis:1996. Fertil Steril. 67:817–821. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Darehdori AS, Dastjerdi MN, Dahim H, et
al: Lack of significance of the BRCA2 promoter methylation status
in different genotypes of the MTHFR a1298c polymorphism in ovarian
cancer cases in Iran. Asian Pac J Cancer Prev. 13:1833–1836. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wu Y, Zhang X, Lin L, et al: Aberrant
methylation of RASSF2A in tumors and plasma of patients with
epithelial ovarian cancer. Asian Pac J Cancer Prev. 15:1171–1176.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Feinberg AP: Phenotypic plasticity and the
epigenetics of human disease. Nature. 447:433–440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Feinberg AP: Epigenetics at the epicenter
of modern medicine. JAMA. 299:1345–1350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Monte NM, Webster KA, Neuberg D, Dressler
GR and Mutter GL: Joint loss of PAX2 and PTEN expression in
endometrial precancers and cancer. Cancer Res. 70:6225–6232. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Zhang H, Zhao X, Liu S, Li J, Wen Z and Li
M: 17betaE2 promotes cell proliferation in endometriosis by
decreasing PTEN via NFkappаB-dependent pathway. Mol Cell
Endocrinol. 317:31–43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Pallarés J, Velasco A, Eritja N, et al:
Promoter hypermethylation and reduced expression of RASSF1A are
frequent molecular alterations of endometrial carcinoma. Mod
Pathol. 21:691–699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Wang D, Chen Q, Zhang C, Ren F and Li T:
DNA hypomethylation of the COX-2 gene promoter is associated with
up-regulation of its mRNA expression in eutopic endometrium of
endometriosis. Eur J Med Res. 17:1–6. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Byun DS, Lee MG, Chae KS, Ryu BG and Chi
SG: Frequent epigenetic inactivation of RASSF1A by aberrant
promoter hypermethylation in human gastric adenocarcinoma. Cancer
Res. 61:7034–7038. 2001.PubMed/NCBI
|
|
22.
|
Maruyama R, Toyooka S, Toyooka KO, et al:
Aberrant promoter methylation profile of bladder cancer and its
relationship to clinicopathological features. Cancer Res.
61:8659–8663. 2001.PubMed/NCBI
|
|
23.
|
Kuroki T, Trapasso F, Yendamuri S, et al:
Promoter hypermethylation of RASSF1A in esophageal squamous cell
carcinoma. Clin Cancer Res. 9:1441–1445. 2003.PubMed/NCBI
|
|
24.
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Nasu K, Kawano Y, Tsukamoto Y, et al:
Aberrant DNA methylation status of endometriosis: Epigenetics as
the pathogenesis, biomarker and therapeutic target. J Obstet
Gynaecol Res. 37:683–695. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Balch C, Yan P, Craft T, et al:
Antimitogenic and chemosensitizing effects of the methylation
inhibitor zebularine in ovarian cancer. Mol Cancer Ther.
4:1505–1514. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kang S, Lee JM, Jeon ES, et al: RASSF1A
hepermethylation and its inverse correlation with BRAF and/or KRAS
mutations in MSI-associated endometrial carcinoma. Int J Cancer.
119:1316–1321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Donninger H, Vos MD and Clark GJ: The
RASSF1A tumor suppressor. J Cell Sci. 120:3163–3172. 2007.
View Article : Google Scholar : PubMed/NCBI
|
